Millipore Sigma Vibrant Logo

IM51 Anti-MMP-2 (Ab-4) Mouse mAb (75-7F7)

Anti-MMP-2 (Ab-4) Mouse mAb (75-7F7): Ficha de datos de seguridad (MSDS o SDS), certificado de análisis y de calidad (CoA y CoQ), expedientes, folletos y otros documentos disponibles.

Sinónimos: Anti-72 kDa Gelatinase, Anti-Gelatinase A, Anti-Matrix Metalloproteinase 2

IM51
Ver precios y disponibilidad

Descripción

Replacement Information

Tabla espec. clave

Species ReactivityHostAntibody Type
B, H, MMMonoclonal Antibody

Precios y disponibilidad

Número de referencia DisponiblidadEmbalaje Cant./Env. Precio Cantidad
IM51-100UG
Comprobando disponibilidad...
—
Disponibilidad a confirmar Disponibilidad a confirmar
Ingrese cantidad 
Suspendido
Cantidades limitadas disponibles
Debe confirmarse disponibilidad
    El resto: se avisará
      El resto: se avisará
      Se avisará
      Póngase en contacto con el Servicio de Atención al Cliente
      Contact Customer Service

      		 Ampolla de plást. 100 μg
      Recuperando precio...
      No pudo obtenerse el precio
      La cantidad mínima tiene que ser múltiplo de
      Maximum Quantity is
      Al finalizar el pedido Más información
      Ahorró ()
       
      —
      Solicitar precio
      		 —
      Description
      OverviewRecognizes the ~72 kDa latent and the ~66 kDa active forms of MMP-2.
      Catalogue NumberIM51
      Brand Family Calbiochem®
      SynonymsAnti-72 kDa Gelatinase, Anti-Gelatinase A, Anti-Matrix Metalloproteinase 2
      Application Data
      Detection of human MMP-2 by immunoblotting. Sample: Conditioned medium of normal human skin fibroblasts CCD-41SK cells. Primary antibody: Anti-MMP-2 (Ab-4) Mouse mAb (75-7F7) (Cat. No. IM51) (1 µg/ml). Detection: chemiluminescence.
      References
      ReferencesCottam, D. W. and Rees, R. C., 1993. Intl. J. Oncol. 2, 861.
      Fujimoto, N., et al. 1993. Clinica Chimica Acta. 221, 91.
      Stetler-Stevenson, W. G., et al. 1993. FASEB J. 7, 1434.
      Woessner, J. F., 1991. FASEB J. 5, 2145.
      Liotta, L. A. and Stetler-Stevenson, W. G., 1990. in Sem. Cancer Biol., ed. M. M. Gottesman. Vol. 1(2), 99.
      Product Information
      DeclarationManufactured by Daiichi Fine Chemical Co., Ltd. Not available for sale in Japan.
      FormLiquid
      FormulationIn 100 mM sodium phosphate buffer, 0.1% BSA, pH 7.0.
      Negative controlMMP-9 protein (Cat. Nos. PF024 or PF038)
      Positive controlMMP-2 protein (Cat. Nos. PF023 or PF037)
      Preservative≤0.1% sodium azide
      Quality LevelMQ100
      Applications
      Application ReferencesImmunoblotting Fujimoto, N., et al. 1993. Clinica Chimica Acta. 221, 91. Paraffin Sections Tsunezuka, Y., et al. 1996. Cancer Res., 56, 5678. Immunohistochemistry Nakagawa, T., et al. 1994. J. Neurosurg. 81, 69.
      Key Applications Frozen Sections
      Immunoblotting (Western Blotting)
      Paraffin Sections
      Application NotesFrozen Sections (see application references)
      Immunoblotting (1 µg/ml, see application references)
      Paraffin Sections (see application references)
      Application CommentsThis antibody does not cross-react with human MMP-1, MMP-3, MMP-7, MMP-8, MMP-9 or MMP-13. Antibody should be titrated for optimal results in individual systems.
      Biological Information
      Immunogenhuman MMP-2 derived from conditioned medium of CCD-41SK skin fibroblasts
      ImmunogenHuman
      Clone75-7F7
      HostMouse
      IsotypeIgG₁
      Species Reactivity
      • Bovine
      • Human
      • Mouse
      Antibody TypeMonoclonal Antibody
      Concentration Label Please refer to vial label for lot-specific concentration
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Blue Ice Only
      Toxicity Standard Handling
      Storage -20°C
      Avoid freeze/thaw Avoid freeze/thaw
      Do not freeze Ok to freeze
      Special InstructionsFollowing initial thaw, aliquot and freeze (-20°C).
      Packaging Information
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Número de referencia GTIN
      IM51-100UG 07790788053802

      Documentation

      Anti-MMP-2 (Ab-4) Mouse mAb (75-7F7) Certificados de análisis

      CargoNúmero de lote
      IM51

      Referencias bibliográficas

      Visión general referencias
      Cottam, D. W. and Rees, R. C., 1993. Intl. J. Oncol. 2, 861.
      Fujimoto, N., et al. 1993. Clinica Chimica Acta. 221, 91.
      Stetler-Stevenson, W. G., et al. 1993. FASEB J. 7, 1434.
      Woessner, J. F., 1991. FASEB J. 5, 2145.
      Liotta, L. A. and Stetler-Stevenson, W. G., 1990. in Sem. Cancer Biol., ed. M. M. Gottesman. Vol. 1(2), 99.
      Ficha técnica

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision27-August-2007 RFH
      SynonymsAnti-72 kDa Gelatinase, Anti-Gelatinase A, Anti-Matrix Metalloproteinase 2
      ApplicationFrozen Sections (see application references)
      Immunoblotting (1 µg/ml, see application references)
      Paraffin Sections (see application references)
      Application Data
      Detection of human MMP-2 by immunoblotting. Sample: Conditioned medium of normal human skin fibroblasts CCD-41SK cells. Primary antibody: Anti-MMP-2 (Ab-4) Mouse mAb (75-7F7) (Cat. No. IM51) (1 µg/ml). Detection: chemiluminescence.
      DescriptionPurified mouse monoclonal antibody. Recognizes the ~72 kDa latent and the ~66 kDa active forms of MMP-2.
      BackgroundMatrix metalloproteinases (MMPs) are a family of enzymes that are responsible for the degradation of extracellular matrix components such as collagen, laminin and proteoglycans. In addition to sequence homology, all MMPs share the following characteristics: the catalytic mechanism is dependent upon a zinc ion at the active center, they cleave one or more extracellular matrix components, they are secreted as zymogens which are activated by removal of an ~10 kDa segment from the N-terminus and they are inhibited by tissue inhibitor of metalloproteinases (TIMP). These enzymes are involved in normal physiological processes such as embryogenesis and tissue remodeling and may play an important role in arthritis, periodontitis, and metastasis. MMP-2 (Gelatinase A, 72 kDa gelatinase, type IV collagenase, TBE-1) is secreted as a 72 kDa zymogen which is proteolytically processed to the 66 kDa active form. MMP-2, along with its most closely related member of the MMP family, MMP-9, show substrate specificity toward type IV and V collagens, gelatin and elastin. Numerous studies have shown a correlation between collagenase expression and metastatic potential and suggest that it may be a useful marker for the diagnosis or prognosis of cancer.
      HostMouse
      Immunogen speciesHuman
      Immunogenhuman MMP-2 derived from conditioned medium of CCD-41SK skin fibroblasts
      Clone75-7F7
      IsotypeIgG₁
      Speciesbovine, human, mouse, not rat
      Positive controlMMP-2 protein (Cat. Nos. PF023 or PF037)
      Negative controlMMP-9 protein (Cat. Nos. PF024 or PF038)
      FormLiquid
      FormulationIn 100 mM sodium phosphate buffer, 0.1% BSA, pH 7.0.
      Concentration Label Please refer to vial label for lot-specific concentration
      Preservative≤0.1% sodium azide
      CommentsThis antibody does not cross-react with human MMP-1, MMP-3, MMP-7, MMP-8, MMP-9 or MMP-13. Antibody should be titrated for optimal results in individual systems.
      Storage Avoid freeze/thaw
      -20°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing initial thaw, aliquot and freeze (-20°C).
      Toxicity Standard Handling
      ReferencesCottam, D. W. and Rees, R. C., 1993. Intl. J. Oncol. 2, 861.
      Fujimoto, N., et al. 1993. Clinica Chimica Acta. 221, 91.
      Stetler-Stevenson, W. G., et al. 1993. FASEB J. 7, 1434.
      Woessner, J. F., 1991. FASEB J. 5, 2145.
      Liotta, L. A. and Stetler-Stevenson, W. G., 1990. in Sem. Cancer Biol., ed. M. M. Gottesman. Vol. 1(2), 99.
      Application referencesImmunoblotting Fujimoto, N., et al. 1993. Clinica Chimica Acta. 221, 91. Paraffin Sections Tsunezuka, Y., et al. 1996. Cancer Res., 56, 5678. Immunohistochemistry Nakagawa, T., et al. 1994. J. Neurosurg. 81, 69.